Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Mouse, Rat, Bovine, Pig
(tested or 100% immunogen sequence identity)
Western blot (1:1000)
MLC2 / MYL9 antibody was raised against phospho-peptide corresponding to residues surroundingSer19 of human myosin light chain 2 (smooth muscle) (KLH coupled).
Detects endogenous levels of human myosin light chain 2 (smooth muscle) only when phosphorylated at serine 19 at 18kD. Does not cross-react with the cardiac isoform of myosin light chain 2. Species cross-reactivity: mouse and rat.
Suitable for use in ELISA, Western Blot, Immunohistochemistry, and Immunocytochemistry. Western Blot: 1:1000. Immunohistochemistry: 1:100. Immunocytochemistry: (IF) 1:50.
10 mM HEPES, pH 7.5, 150 mM NaCl, 0.1 mg/ml BSA, 0.02% Sodium Azide, 50% Glycerol
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
Myosin, the major component of muscle filaments, is a long asymmetric molecule containing a globular head and a long tail. It is composed of two heavy chains and four light chains. Phosphorylation of myosin light chain in response to increased calcium levels leads to contraction. Myosin light chain phosphatase acts to regulate muscle contraction by dephosphorylating activated myosin light chain.
Morgana acts as an oncosuppressor in chronic myeloid leukemia. Panuzzo C, Rocca S, Familiari U, Piazza R, Crivellaro S, Carr[Character e0] G, Ferretti R, Fusella F, Giugliano E, Camporeale A, Franco I, Miniscalco B, Cutrin JC, Turco E, Silengo L, Hirsch E, Rege-Cambrin G, Gambacorti-Passerini C, Pandolfi PP, Papotti M, Saglio G, Tarone G, Morotti A, Brancaccio M. Blood. Feb; [Full Text Article]